BioCatalystWatch
PHIOWorkspace / PHIO / OverviewCompany library
Phio Pharmaceuticals Corp. logo

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (PHIO)

Website

Price
Market cap
Next catalystExpected Q1 2027PH-762 — planned Phase 2b neoadjuvant cSCC study · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

PH-762

PD-1

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

PH-762

PD-1

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Other pipelines

INTASYL

Cbl-b

PreINDP1P2P3FilingApproved

History / paused

PH-762

PD-1

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

PHIO PR & News

PR & News

PHIO SEC archive